NIFTY  9,386.15  -0.55%
  SENSEX  30,365.20  -0.67%
 CURRENCY  Rs  64.55/$ 72.63/€, 83.84/£
  GOLD  28,906.00  0.42%
  SILVER  40,119.00  0.61%
  DAX  12,619.50  -0.15%
  FTSE  7,496.34  0.34%
  CAC  5,322.88  -0.02%
  HANG SENG  25,403.20  0.05%
  NIKKEI  19,613.30  -0.33%
  Shanghai Composite  3,061.95  -0.23%
  DOW JONES  20,894.80  0.43%
  NASDAQ  6,133.62  0.82%
  S&P 500  2,394.02  0.52%
CCI : Approves Amalgamation Of Videocon D2H Into And With Dish TV CCI : Approves Acquisition Of Up To 6% Stake By Aceville In Flipkart EARNINGS REPORT : National Peroxide Q4 PAT Rs 15.7 Cr Vs Rs 7.4 Cr YoY EARNINGS REPORT : National Peroxide Q4 Total Income From Ops Rs 68.9 Cr Vs Rs 61.4 Cr YoY

USFDA Turns Its Gaze On Ranbaxy

Video:

Play this video

January 13: Ranbaxy today said that it has received Form 483 from the U.S. FDA with some observations for its Toansa API plant. Analysts say that if the company is not able to address the concerns of U.S. FDA then an import alert could be issued which would have a significant impact on the company's financials. Bloomberg TV India’s Priya Sheth shares a detailed report on the same.